SG11201601932UA - Adeno-associated virus factor viii vectors - Google Patents
Adeno-associated virus factor viii vectorsInfo
- Publication number
- SG11201601932UA SG11201601932UA SG11201601932UA SG11201601932UA SG11201601932UA SG 11201601932U A SG11201601932U A SG 11201601932UA SG 11201601932U A SG11201601932U A SG 11201601932UA SG 11201601932U A SG11201601932U A SG 11201601932UA SG 11201601932U A SG11201601932U A SG 11201601932UA
- Authority
- SG
- Singapore
- Prior art keywords
- adeno
- factor viii
- associated virus
- virus factor
- vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877042P | 2013-09-12 | 2013-09-12 | |
| PCT/US2014/054960 WO2015038625A1 (fr) | 2013-09-12 | 2014-09-10 | Vecteurs du facteur viii de virus associé aux adénovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601932UA true SG11201601932UA (en) | 2016-04-28 |
Family
ID=51585244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601932UA SG11201601932UA (en) | 2013-09-12 | 2014-09-10 | Adeno-associated virus factor viii vectors |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US9504762B2 (fr) |
| EP (2) | EP3044231B1 (fr) |
| JP (4) | JP6735672B2 (fr) |
| KR (2) | KR102484396B1 (fr) |
| CN (2) | CN105636981B (fr) |
| AR (1) | AR097657A1 (fr) |
| AU (1) | AU2014318890B2 (fr) |
| CA (3) | CA3178379A1 (fr) |
| CL (1) | CL2016000502A1 (fr) |
| CY (2) | CY1124213T1 (fr) |
| DK (1) | DK3044231T3 (fr) |
| ES (1) | ES2813698T3 (fr) |
| FI (1) | FIC20230007I1 (fr) |
| FR (1) | FR23C1007I2 (fr) |
| HK (1) | HK1226416A1 (fr) |
| HR (1) | HRP20201324T1 (fr) |
| HU (2) | HUE050484T2 (fr) |
| IL (2) | IL244404B (fr) |
| LT (2) | LT3044231T (fr) |
| MX (2) | MX2016003262A (fr) |
| NL (1) | NL301222I2 (fr) |
| NO (1) | NO2023003I1 (fr) |
| NZ (1) | NZ716549A (fr) |
| PE (1) | PE20160769A1 (fr) |
| PH (1) | PH12016500328A1 (fr) |
| PL (1) | PL3044231T3 (fr) |
| PT (1) | PT3044231T (fr) |
| RS (1) | RS61039B1 (fr) |
| RU (1) | RU2710307C2 (fr) |
| SG (1) | SG11201601932UA (fr) |
| SI (1) | SI3044231T1 (fr) |
| TW (1) | TWI632239B (fr) |
| WO (1) | WO2015038625A1 (fr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201210357D0 (en) | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
| ES2813698T3 (es) | 2013-09-12 | 2021-03-24 | Biomarin Pharm Inc | Vectores de AAV que comprenden un gen que codifica el factor VIII |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| EP3270944B1 (fr) * | 2015-03-17 | 2019-10-23 | Vrije Universiteit Brussel | Systèmes d'expression spécifiques du foie optimisés pour fviii et fix |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| CN108093639B (zh) * | 2015-04-16 | 2022-07-19 | 埃默里大学 | 用于肝脏中蛋白质表达的重组启动子和载体及其用途 |
| TWI756185B (zh) | 2015-09-24 | 2022-03-01 | 美商拜奧馬林製藥公司 | 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物 |
| BR112018008519A2 (pt) * | 2015-10-28 | 2018-11-06 | Sangamo Therapeutics Inc | construtos específicos de fígado, cassetes de expressão de fator viii e métodos de uso dos mesmos |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| CA3005565A1 (fr) * | 2015-11-13 | 2017-05-18 | Baxalta Incorporated | Vecteurs viraux codant pour des variants du facteur viii de recombinaison avec une expression augmentee pour la therapie genique de l'hemophilie a |
| SG10202106307UA (en) * | 2015-11-13 | 2021-07-29 | Takeda Pharmaceuticals Co | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| RU2762257C2 (ru) * | 2016-04-15 | 2021-12-17 | Зе Трастис Оф Зе Юниверсити Оф Пенсильвания | Генная терапия для лечения гемофилии a |
| CA3023473A1 (fr) | 2016-05-25 | 2017-11-30 | Lonza Houston Inc. | Procedes d'isolement de virus adeno-associe a l'aide d'un sel de polydiallyldialkylammonium |
| US11584780B2 (en) | 2016-07-26 | 2023-02-21 | Biomarin Pharmaceutical Inc. | Adeno-associated virus capsid proteins |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| US20200237930A1 (en) * | 2017-08-01 | 2020-07-30 | Spark Therapeutics, Inc. | Factor viii (fviii) gene therapy methods |
| US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| WO2019222132A1 (fr) | 2018-05-14 | 2019-11-21 | Biomarin Pharmaceutical Inc. | Expression stable de vecteurs vaa chez des sujets jeunes |
| AU2019306194A1 (en) | 2018-07-16 | 2021-02-04 | Baxalta GmbH | Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression |
| AU2018434176A1 (en) * | 2018-07-27 | 2021-01-28 | Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh | Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| CA3116283A1 (fr) * | 2018-10-12 | 2020-04-16 | Genzyme Corporation | Generation de pah humain ameliore pour le traitement d'une pku severe au moyen d'une therapie de remplacement genique dirigee dans le foie |
| IL314658A (en) * | 2019-01-16 | 2024-09-01 | Baxalta Inc | Viral vectors encoding recombinant FVIII variants with enhanced expression for hemophilia A gene therapy |
| WO2020168362A1 (fr) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée |
| CN113874513A (zh) * | 2019-03-13 | 2021-12-31 | 世代生物公司 | 非病毒dna载体及其用于表达fviii治疗剂的用途 |
| JP6831943B1 (ja) | 2019-10-24 | 2021-02-17 | 三ツ星ベルト株式会社 | 摩擦伝動ベルトおよびその製造方法 |
| CA3158995A1 (fr) * | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Elements regulateurs de transcription |
| JP2023506171A (ja) | 2019-12-12 | 2023-02-15 | 武田薬品工業株式会社 | 発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクターを使用する、血友病ａの遺伝子療法 |
| WO2021236908A2 (fr) | 2020-05-20 | 2021-11-25 | Biomarin Pharmaceutical Inc. | Utilisation de protéines régulatrices pour la production d'un virus adéno-associé |
| KR20230078805A (ko) | 2020-11-02 | 2023-06-02 | 바이오마린 파머수티컬 인크. | 아데노-연관 바이러스의 농축 공정 |
| WO2022264040A1 (fr) | 2021-06-14 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Thérapie génique contre l'hémophilie a faisant appel à des vecteurs viraux codant pour des variants de fviii recombinés à expression accrue |
| KR20240023638A (ko) * | 2021-06-22 | 2024-02-22 | 화이자 인코포레이티드 | 곤충 세포에서의 아데노-연관 바이러스 벡터의 생산 |
| JP2024527000A (ja) * | 2021-07-28 | 2024-07-19 | バイオマリン ファーマシューティカル インコーポレイテッド | 大規模なアデノ随伴ウイルス産生システム |
| WO2023028456A1 (fr) * | 2021-08-23 | 2023-03-02 | Bioverativ Therapeutics Inc. | Gènes de facteur viii optimisés |
| WO2023036054A2 (fr) * | 2021-09-08 | 2023-03-16 | Inspirar Limited | Composition et méthode de traitement de l'hémophilie |
| WO2023135273A2 (fr) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions de molécules d'adn codant pour le facteur viii, leurs procédés de préparation et leurs méthodes d'utilisation |
| AR128760A1 (es) * | 2022-03-11 | 2024-06-12 | Homology Medicines Inc | Vectores de expresión con promotores dobles bidireccionales y sus usos |
| WO2023205300A2 (fr) * | 2022-04-20 | 2023-10-26 | Asklepios Biopharmaceutical, Inc. | Virus adéno-associé thérapeutique utilisant un acide nucléique à codons optimisés codant pour un facteur viii |
| TW202417631A (zh) | 2022-09-22 | 2024-05-01 | 美商拜奧馬林製藥公司 | 用ａａｖ基因治療載體治療心肌病 |
| TW202421788A (zh) | 2022-09-22 | 2024-06-01 | 美商拜奧馬林製藥公司 | 用ａａｖ基因療法載體治療致心律不整性心肌病 |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
| WO2024074143A1 (fr) * | 2022-10-08 | 2024-04-11 | Lingyi Biotech Co., Ltd. | Construction pour améliorer l'expression génique |
| CN116555266A (zh) * | 2023-06-09 | 2023-08-08 | 呈诺再生医学科技(北京)有限公司 | 肝脏特异性表达的重组启动子和载体及其在肝脏相关疾病治疗中的应用 |
| CN118064436B (zh) * | 2024-04-18 | 2024-07-26 | 上海凌医生物科技有限公司 | 一种增强基因表达的嵌合启动子 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| DE3485810T2 (de) | 1983-05-27 | 1992-12-10 | Texas A & M University Syst | Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| WO1995002697A1 (fr) | 1993-07-13 | 1995-01-26 | Rhone-Poulenc Rorer S.A. | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US6521225B1 (en) | 1996-09-06 | 2003-02-18 | Chiron Corporation | AAV vectors |
| WO2000011149A1 (fr) * | 1998-08-24 | 2000-03-02 | Uab Research Foundation | Procedes de production de virus associes aux adenovirus recombinants a titre eleve |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| WO2003074714A1 (fr) | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Systeme d'expression de baculovirus |
| DK1804839T3 (da) | 2004-09-22 | 2012-04-10 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| CN1286981C (zh) * | 2004-11-30 | 2006-11-29 | 华中科技大学同济医学院附属同济医院 | 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法 |
| EP1739179A1 (fr) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Transfection stable exempt de sérum et production des protéines recombinantes humaines dans des lignées cellulaires humaines |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US7943379B2 (en) | 2008-04-30 | 2011-05-17 | Nationwide Children's Hospital, Inc. | Production of rAAV in vero cells using particular adenovirus helpers |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| JP6029674B2 (ja) * | 2011-10-18 | 2016-11-24 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用 |
| CN103215308B (zh) * | 2013-02-01 | 2015-12-23 | 中国科学院苏州生物医学工程技术研究所 | 表达重组人fviii的整合质粒、细胞株及其构建方法和应用 |
| ES2813698T3 (es) | 2013-09-12 | 2021-03-24 | Biomarin Pharm Inc | Vectores de AAV que comprenden un gen que codifica el factor VIII |
-
2014
- 2014-09-10 ES ES14771729T patent/ES2813698T3/es active Active
- 2014-09-10 WO PCT/US2014/054960 patent/WO2015038625A1/fr active Application Filing
- 2014-09-10 SI SI201431647T patent/SI3044231T1/sl unknown
- 2014-09-10 RU RU2016113702A patent/RU2710307C2/ru active
- 2014-09-10 AU AU2014318890A patent/AU2014318890B2/en active Active
- 2014-09-10 CA CA3178379A patent/CA3178379A1/fr active Pending
- 2014-09-10 PL PL14771729T patent/PL3044231T3/pl unknown
- 2014-09-10 RS RS20201018A patent/RS61039B1/sr unknown
- 2014-09-10 PE PE2016000353A patent/PE20160769A1/es unknown
- 2014-09-10 SG SG11201601932UA patent/SG11201601932UA/en unknown
- 2014-09-10 HU HUE14771729A patent/HUE050484T2/hu unknown
- 2014-09-10 JP JP2016542067A patent/JP6735672B2/ja active Active
- 2014-09-10 EP EP14771729.2A patent/EP3044231B1/fr active Active
- 2014-09-10 NZ NZ716549A patent/NZ716549A/en unknown
- 2014-09-10 DK DK14771729.2T patent/DK3044231T3/da active
- 2014-09-10 PT PT147717292T patent/PT3044231T/pt unknown
- 2014-09-10 CA CA3178384A patent/CA3178384A1/fr active Pending
- 2014-09-10 CN CN201480050615.3A patent/CN105636981B/zh active Active
- 2014-09-10 LT LTEP14771729.2T patent/LT3044231T/lt unknown
- 2014-09-10 KR KR1020167009492A patent/KR102484396B1/ko active IP Right Grant
- 2014-09-10 KR KR1020227046233A patent/KR20230006058A/ko not_active Application Discontinuation
- 2014-09-10 MX MX2016003262A patent/MX2016003262A/es unknown
- 2014-09-10 CN CN202011117582.3A patent/CN112538501A/zh active Pending
- 2014-09-10 CA CA2921232A patent/CA2921232C/fr active Active
- 2014-09-10 US US14/482,648 patent/US9504762B2/en active Active
- 2014-09-10 EP EP20182970.2A patent/EP3770169A1/fr active Pending
- 2014-09-12 AR ARP140103423A patent/AR097657A1/es unknown
- 2014-09-12 TW TW103131665A patent/TWI632239B/zh active
-
2016
- 2016-02-18 PH PH12016500328A patent/PH12016500328A1/en unknown
- 2016-03-03 IL IL244404A patent/IL244404B/en unknown
- 2016-03-04 CL CL2016000502A patent/CL2016000502A1/es unknown
- 2016-03-11 MX MX2021012014A patent/MX2021012014A/es unknown
- 2016-10-14 US US15/294,310 patent/US10463718B2/en active Active
- 2016-12-22 HK HK16114574A patent/HK1226416A1/zh unknown
-
2017
- 2017-11-17 US US15/816,596 patent/US20180161403A1/en not_active Abandoned
-
2019
- 2019-08-14 JP JP2019148912A patent/JP7523211B2/ja active Active
- 2019-09-30 US US16/588,130 patent/US11406690B2/en active Active
-
2020
- 2020-08-25 HR HRP20201324TT patent/HRP20201324T1/hr unknown
- 2020-08-31 CY CY20201100814T patent/CY1124213T1/el unknown
-
2021
- 2021-02-18 JP JP2021024332A patent/JP2021072871A/ja not_active Withdrawn
- 2021-09-30 IL IL286859A patent/IL286859A/en unknown
-
2022
- 2022-06-30 US US17/854,286 patent/US20220339262A1/en active Pending
-
2023
- 2023-01-11 HU HUS2300003C patent/HUS2300003I1/hu unknown
- 2023-01-12 NO NO2023003C patent/NO2023003I1/no unknown
- 2023-02-02 FR FR23C1007C patent/FR23C1007I2/fr active Active
- 2023-02-08 FI FIC20230007C patent/FIC20230007I1/fi unknown
- 2023-02-20 CY CY2023006C patent/CY2023006I2/el unknown
- 2023-02-20 LT LTPA2023508C patent/LTPA2023508I1/lt unknown
- 2023-02-24 NL NL301222C patent/NL301222I2/nl unknown
- 2023-08-04 JP JP2023127698A patent/JP2023133597A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286859A (en) | Adeno-associated virus factor viii vectors | |
| HK1217916A1 (zh) | 嵌合腺相關病毒/博卡病毒細小病毒載體 | |
| HK1220617A1 (zh) | 因子 多肽調配物 | |
| GB201318347D0 (en) | Retroviral vectors | |
| HRP20180452T1 (hr) | Peptidi | |
| HK1211596A1 (en) | Peptide | |
| HK1211595A1 (en) | Peptide | |
| GB201315130D0 (en) | Peptides | |
| GB201313535D0 (en) | Hairdryers | |
| GB201308772D0 (en) | Vectors | |
| GB201316660D0 (en) | Peptides | |
| GB201300381D0 (en) | Peptides | |
| GB201305465D0 (en) | Novel peptides | |
| GB201317839D0 (en) | Anti-Microbial peptides | |
| GB201318295D0 (en) | Modified comb | |
| GB201304119D0 (en) | Hairdryers | |
| GB201306435D0 (en) | Vector |